Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: First clinical results of a prospective pilot study

Journal of Oral and Maxillofacial Surgery

Volumn 69, Issue 1, 2011, Pages 84-91

  Pautke, Christoph ^a   Bauer, Florian ^b   Otto, Sven ^a   Tischer, Thomas ^c   Steiner, Timm ^b   Weitz, Jochen ^b   Kreutzer, Kilian ^b   Hohlweg Majert, Bettina ^b   Wolff, Klaus Dietrich ^b   Hafner, Sigurd ^a   Mast, Gerson ^a   Ehrenfeld, Michael ^a   Strzenbaum, Stephen R ^d   Kolk, Andreas ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLINDAMYCIN; DOXYCYCLINE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ANASTOMOSIS DEHISCENCE; ARTICLE; BONE METASTASIS; BONE NECROSIS; BONE RESECTION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENT LIGHTING; HUMAN; JAW OSTEONECROSIS; MALE; PILOT STUDY; POSTOPERATIVE PERIOD;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DEBRIDEMENT; DIPHOSPHONATES; DOXYCYCLINE; FEMALE; FLUORESCENCE; FLUORESCENT DYES; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; PILOT PROJECTS; PROSPECTIVE STUDIES; SURGICAL FLAPS; SURGICAL WOUND DEHISCENCE; TREATMENT OUTCOME; WOUND HEALING;

EID: 78650288904     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2010.07.014     Document Type: Article

References (49)

1. J.R. Berenson, O. Yellin, and R.V. Boccia Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss Clin Cancer Res 14 2008 6289
2. J.R. Berenson, A. Lichtenstein, and L. Porter Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma Myeloma Aredia Study Group N Engl J Med 334 1996 488
3. H.T. Hatoum, S.J. Lin, and M.R. Smith Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: Analysis of a national medical claims database Cancer 113 2008 1438
4. R.A. Kyle, G.C. Yee, and M.R. Somerfield American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma J Clin Oncol 25 2007 2464
5. C. Scavelli, G. Di Pietro, and T. Cirulli Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma Mol Cancer Ther 6 2007 3256
6. A. Corso, E. Ferretti, and M. Lunghi Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: A possible mechanism for its antitumor effect Cancer 104 2005 118
7. M.D. Michaelson, and M.R. Smith Bisphosphonates for treatment and prevention of bone metastases J Clin Oncol 23 2005 8219
8. B.E. Hillner, J.N. Ingle, and R.T. Chlebowski American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 2003 4042
9. J.R. Berenson, B.E. Hillner, and R.A. Kyle American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma J Clin Oncol 20 2002 3719
10. D.P. Dearnaley, M.D. Mason, and M.K. Parmar Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 10 2009 872
11. A. Lipton, R. Cook, and F. Saad Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 113 2008 193
12. C.A. Migliorati Bisphosphanates and oral cavity avascular bone necrosis J Clin Oncol 21 2003 4253
13. J. Wang, N.M. Goodger, and M.A. Pogrel Osteonecrosis of the jaws associated with cancer chemotherapy J Oral Maxillofac Surg 61 2003 1104
14. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic J Oral Maxillofac Surg 61 2003 1115
15. N. Raje, S.B. Woo, and K. Hande Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw Clin Cancer Res 14 2008 2387
16. C. Walter, B. Al-Nawas, and A. du Bois Incidence of bisphosphonate- associated osteonecrosis of the jaws in breast cancer patients Cancer 115 2009 1631
17. T. Boonyapakorn, I. Schirmer, and P.A. Reichart Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies Oral Oncol 44 2008 857
18. C. Walter, B. Al-Nawas, and K.A. Grotz Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate Eur Urol 54 2008 1066
19. E.P. Wang, L.B. Kaban, and G.J. Strewler Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy J Oral Maxillofac Surg 65 2007 1328
20. A. Badros, E. Terpos, and E. Katodritou Natural history of osteonecrosis of the jaw in patients with multiple myeloma J Clin Oncol 26 2008 5904
21. A. Kyrgidis, K. Vahtsevanos, and G. Koloutsos Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients J Clin Oncol 26 2008 4634
22. S. Khosla, D. Burr, and J. Cauley Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479
23. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 65 2007 369
24. S.L. Ruggiero, T.B. Dodson, and L.A. Assael American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws2009 update J Oral Maxillofac Surg 67 2009 2
25. M.A. Dimopoulos, E. Kastritis, and C. Bamia Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann Oncol 20 2009 117
26. K. Vahtsevanos, A. Kyrgidis, and E. Verrou Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 2009 5356
27. A. Badros, D. Weikel, and A. Salama Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors J Clin Oncol 24 2006 945
28. A. Bamias, E. Kastritis, and C. Bamia Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors J Clin Oncol 23 2005 8580
29. A. Corso, M. Varettoni, and P. Zappasodi A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma Leukemia 21 2007 1545
30. R.E. Marx, J.E. Cillo Jr, and J.J. Ulloa Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 65 2007 2397
31. H. Mawardi, N. Treister, and P. Richardson Sinus tractsAn early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg 67 2009 593
32. T. Mcke, S. Haarmann, and K.D. Wolff Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction J Craniomaxillofac Surg 37 2009 291
33. S.L. Engroff, and D.D. Kim Treating bisphosphonate osteonecrosis of the jaws: Is there a role for resection and vascularized reconstruction? J Oral Maxillofac Surg 65 2007 2374
34. C. Pautke, F. Bauer, and O. Bissinger Tetracycline bone fluorescence: A valuable marker for osteonecrosis characterization and therapy J Oral Maxillofac Surg 68 2010 125
35. C. Pautke, F. Bauer, and T. Tischer Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws J Oral Maxillofac Surg 67 2009 471
36. S. Pozzi, S. Vallet, and S. Mukherjee High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties Clin Cancer Res 15 2009 5829
37. S. Otto, S. Hafner, and K.A. Grotz The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw J Oral Maxillofac Surg 67 2009 589
38. L. Montebugnoli, L. Felicetti, and D.B. Gissi Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 2007 473
39. O. Filleul, E. Crompot, and S. Saussez Bisphosphonate-induced osteonecrosis of the jaw: A review of 2,400 patient cases J Cancer Res Clin Oncol 136 2010 1117
40. F.S. O'Ryan, S. Khoury, and W. Liao Intravenous bisphosphonate-related osteonecrosis of the jaw: Bone scintigraphy as an early indicator J Oral Maxillofac Surg 67 2009 1363
41. A.O. Hoff, B.B. Toth, and K. Altundag Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826
42. T. Van den Wyngaert, T. Claeys, and M.T. Huizing Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome Ann Oncol 20 2009 331
43. D.C. Stanton, and E. Balasanian Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: Review of 33 surgical cases J Oral Maxillofac Surg 67 2009 943
44. G. Markose, F.R. Mackenzie, and W.J. Currie Bisphosphonate osteonecrosis: A protocol for surgical management Br J Oral Maxillofac Surg 47 2009 294
45. E.R. Carlson, and J.D. Basile The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 67 2009 85
46. K.E. Fleisher, S. Doty, and S. Kottal Tetracycline-guided debridement and cone beam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: A technical note J Oral Maxillofac Surg 66 2008 2646
47. P. Vescovi, M. Manfredi, and E. Merigo Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 66 2008 831
48. C. Pautke, T. Tischer, and A. Neff In vivo tetracycline labeling of bone: An intraoperative aid in the surgical therapy of osteoradionecrosis of the mandible Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 2006 e10
49. A. Bedogni, S. Blandamura, and Z. Lokmic Bisphosphonate-associated jawbone osteonecrosis: A correlation between imaging techniques and histopathology Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 2008 358